Novel Factor V C2-Domain Mutation (R2074H) in Two Families with Factor V Deficiency and Bleeding

I. Schrijver; R. Houissa-Kastally; C. D. Jones; K. C. Garcia; J. L. Zehnder

doi:10.1055/s-0037-1612988

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2002; 87(02): 294-299
DOI: 10.1055/s-0037-1612988

Letters to the Editor

Schattauer GmbH

Novel Factor V C2-Domain Mutation (R2074H) in Two Families with Factor V Deficiency and Bleeding

Authors

I. Schrijver

¹Department of Pathology, and the Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, CA; and the Clinical Biology Laboratory, Habib Thameur Hospital, Tunis, Tunisia
R. Houissa-Kastally

¹Department of Pathology, and the Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, CA; and the Clinical Biology Laboratory, Habib Thameur Hospital, Tunis, Tunisia
C. D. Jones

¹Department of Pathology, and the Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, CA; and the Clinical Biology Laboratory, Habib Thameur Hospital, Tunis, Tunisia
K. C. Garcia

¹Department of Pathology, and the Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, CA; and the Clinical Biology Laboratory, Habib Thameur Hospital, Tunis, Tunisia
J. L. Zehnder

¹Department of Pathology, and the Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, CA; and the Clinical Biology Laboratory, Habib Thameur Hospital, Tunis, Tunisia

Abstract

Summary

The molecular basis of Factor V deficiency has been defined in few patients only. We report a homozygous nucleotide change (G6395A) in two Tunisian probands with Factor V deficiency and bleeding episodes. This substitution results in the replacement of an arginine (R) by a histidine (H) in amino acid position 2074, located in the Factor V C2-domain. Mutations in this protein domain have not previously been described. Several lines of evidence support that this sequence variant is indeed disease causing: 1) Crystal structures of Factor V and molecular C2-domain modeling studies of H2074 suggest that the conserved R2074 is required for correct folding; 2) Structure-function studies of selective Factor V mutants (R2074A) demonstrate the importance of R2074 for structural stability of the Factor V C2-domain and for cofactor activity (1); 3) In Factor VIII, point mutations in codon 2209, which corresponds to position 2074 in Factor V, cause hemophilia A.

Keywords

Factor V deficiency - parahemophilia - inherited coagulation disorders - Factor V - bleeding

Full Text

References

References
1 Kim SW, Quinn-Allen MA, Camp JT. et al. Identification of functionally important amino acid residues within the C2-domain of human factor V using alanine-scanning mutagenesis. Biochemistry 2000; 39: 1951-8.
2 Suzuki K, Dahlback B, Stenflo J. Thrombin-catalyzed activation of human coagulation factor V. J Biol Chem 1982; 257: 6556-64.
3 Kane WH, Ichinose A, Hagen FS, Davie EW. Cloning of cDNAs coding for the heavy chain region and connecting region of human factor V, a blood coagulation factor with four types of internal repeats. Biochemistry 1987; 26: 6508-14.
4 Cripe LD, Moore KD, Kane WH. Structure of the gene for human coagulation factor V. Biochemistry 1992; 31: 3777-85.
5 Jenny RJ, Pittman DD, Toole JJ. et al. Complete cDNA and derived amino acid sequence of human factor V. Proc Natl Acad Sci U S A 1987; 84: 4846-50.
6 Gitschier J, Wood WI, Goralka TM. et al. Characterization of the human factor VIII gene. Nature 1984; 312: 326-30.
7 Vehar GA, Keyt B, Eaton D. et al. Structure of human factor VIII. Nature 1984; 312: 337-42.
8 Kane WH, Davie EW. Blood coagulation factors V and VIII: structural and functional similarities and their relationship to hemorrhagic and thrombotic disorders. Blood 1988; 71: 539-55.
9 Seeler RA. Parahemophilia. Factor V deficiency. Med Clin North Am 1972; 56: 119-25.
10 Lak M, Sharifian R, Peyvandi F, Mannucci PM. Symptoms of inherited factor V deficiency in 35 Iranian patients. Br J Haematol 1998; 103: 1067-9.
11 Ehrenforth S, Klarmann D, Zabel B, Scharrer I, Kreuz W. Severe factor V deficiency presenting as subdural haematoma in the newborn [letter]. Eur J Pediatr 1998; 157: 1032.
12 Totan M, Albayrak D. Intracranial haemorrhage due to factor V deficiency. Acta Paediatr 1999; 88: 342-3.
13 Yoneoka Y, Ozawa T, Saitoh A, Arai H. Emergency evacuation of expanding intracerebral haemorrhage in parahaemophilia (coagulation factor V deficiency). Acta Neurochir (Vienna) 1999; 141: 667-8.
14 Salooja N, Martin P, Khair K, Liesner R, Hann I. Severe factor V deficiency and neonatal intracranial haemorrhage: a case report. Haemophilia 2000; 06: 44-6.
15 Girolami A, Simioni P, Scarano L, Girolami B, Marchiori A. Hemorrhagic and thrombotic disorders due to factor V deficiencies and abnormalities: an updated classification. Blood Rev 1998; 12: 45-51.
16 Murray JM, Rand MD, Egan JO, Murphy S, Kim HC, Mann KG. Factor VNew Brunswick: Ala221-to-Val substitution results in reduced cofactor activity. Blood 1995; 86: 18207.
17 Guasch JF, Lensen RP, Bertina RM. Molecular characterization of a type I quantitative factor V deficiency in a thrombosis patient that is “pseudo homozygous” for activated protein C resistance. Thromb Haemost 1997; 77: 252-7.
18 Castoldi E, Kalafatis M, Lunghi B. et al. Molecular bases of pseudohomozygous APC resistance: the compound heterozygosity for FV R506Q and a FV null mutation results in the exclusive presence of FV Leiden molecules in plasma. Thromb Haemost 1998; 80: 403-6.
19 Guasch JF, Cannegieter S, Reitsma PH, van’t Veer-Korthof ET, Bertina RM. Severe coagulation factor V deficiency caused by a 4 bp deletion in the factor V gene. Br J Haematol 1998; 101: 32-9.
20 Lunghi B, Castoldi E, Mingozzi F, Bernardi F, Castaman G. A novel factor V null mutation detected in a thrombophilic patient with pseudo-homozygous APC resistance and in an asymptomatic unrelated subject [letter]. Blood 1998; 92: 1463-4.
21 Zehnder JL, Hiraki DD, Jones CD, Gross N, Grumet FC. Familial coagulation factor V deficiency caused by a novel 4 base pair insertion in the factor V gene: factor V Stanford. Thromb Haemost 1999; 82: 1097-9.
22 Mirochnik O, Halim-Kertanegara N, Henniker AJ, Favaloro EJ, Tiley CR, Herzberg MS, McDonald DA. A novel factor V null mutation at Arg 506 causes a false positive factor V Leiden result. Thromb Haemost 1999; 82: 1198-9.
23 Montefusco MC, Duga S, Asselta T, Santagostino E, Mancuso G, Malcovati M, Mannucci PM, Tenchini ML. A novel two base pair deletion in the factor V gene associated with severe factor V deficiency. Br J Haematol 2000; 111: 1240-6.
24 Castoldi E, Simioni P, Kalafatis M, Lunghi B, Tormene D, Girelli D, Girolami A, Bernardi F. Combinations of 4 mutations (FV R506Q, FV H1299R, FV Y1702C, PT 20210G/A) affecting the prothrombinase complex in a thrombophilic family. Blood 2000; 96: 1443-8.
25 van Wijk R, Nieuwenhuis K, van den Berg M, Huizinga EG, van der Meijden BB, Kraaijenhagen RJ, van Solinge WW. Five novel mutations in the gene for human blood coagulation factor V associated with type I factor V deficiency. Blood 2001; 98: 358-67.
26 van Wijk R, Montefusco MC, Duga S, Asselta R, van Solinge W, Malcovati M, Tenchini ML, Mannucci PM. Coexistence of a novel homozygous nonsense mutation in exon 13 of the factor V gene with the homozygous Leiden mutation in two unrelated patients with severe factor V deficiency. Br J Haematol 2001; 114 (04) 871-4.
27 Cotton RGH. Update on nomenclature for human gene mutations. Human Mutation 1996; 08: 197-202.
28 Bertina RM, Koeleman BPC, Koster T. et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-7.
29 Rosendaal FR, Koster T, Vandenbroucke JP, Reitsma PH. High risk of thrombosis in patients homozygous for factor V Leiden. Blood 1995; 85: 1504-8.
30 Benson DA, Karsch-Mizrachi I, Lipman DJ, Ostell J, Rapp BA, Wheeler DL. GenBank. Nucleic Acids Res 2000; 28: 15-8.
31 Altschul SF, Madden TL, Schaffer AA. et al. Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res 1997; 25: 3389-402.
32 Gandrille S, Greengard JS, Alhenc-Gelas M. et al. Incidence of activated protein C resistance caused by the ARG 506 GLN mutation in factor V in 113 unrelated symptomatic protein C-deficient patients. The French Network on the behalf of INSERM. Blood 1995; 86: 219-24.
33 Kalafatis M, Rand MD, Mann KG. Factor Va-membrane interaction is mediated by two regions located on the light chain of the cofactor. Biochemistry 1994; 33: 486-93.
34 Ortel TL, Devore-Carter D, Quinn-Allen M, Kane WH. Deletion analysis of recombinant human factor V. Evidence for a phosphatidylserine binding site in the second C-type domain. J Biol Chem 1992; 267: 4189-98.
35 Ortel TL, Quinn-Allen MA, Keller FG, Peterson JA, Larocca D, Kane WH. Localization of functionally important epitopes within the second C-type domain of coagulation factor V using recombinant chimeras. J Biol Chem 1994; 269: 15898-905.
36 Macedo-Ribeiro S, Bode W, Huber R. et al. Crystal structures of the membrane-binding C2 domain of human coagulation factor V. Nature 1999; 402: 434-9.
37 Liu ML, Shen BW, Nakaya S. et al. Hemophilic factor VIII C1- and C2- domain missense mutations and their modeling to the 1.5-angstrom human C2-domain crystal structure. Blood 2000; 96: 979-87.
38 Tracy PB, Mann KG. Abnormal formation of the prothrombinase complex: factor V deficiency and related disorders. Hum Pathol 1987; 18: 162-9.